-- Days : -- HRS : -- MIN : -- SEC
Register Now →
|Articles|July 15, 2006

The American Journal of Managed Care

  • July 2006
  • Volume 12
  • Issue 7

Brixner (Am J Manag Care. 2006;12[suppl 7]:S191-S198)

Am J Manag Care.

There were 2 errors in the supplement, "Fracture Prevention in Osteoporosis." First, in Figure 1 on page S192 of the article "Assessment of the Prevalence and Costs of Osteoporosis Treatment Options in a Real-world Setting," by Diana Brixner, PhD, RPh,(2006;12[suppl 7]:S191-S198), the bars representing the VERTNA [Vertebral Efficacy With Risedronate Therapy-North America] study were inadvertently switched with the placebo bars. Second, in the same figure, the acronym VERT-MIN was incorrect; the correct acronym is VERT-MN [Vertebral Efficacy With Risedronate Therapy-Multinational]. The corrected figure appears below.


Related to this article

Andrew D. Zelenetz, MD, PhD, is the chair of the NCCN B-cell Lymphomas panel.  | Image: LinkedIn
The National Comprehensive Cancer Network update on mantle cell lymphoma puts covalent BTK inhibitors, MRD testing, and TP53 sequencing at the center of frontline care, while adding pirtobrutinib and a pair of CAR T-cell therapies for disease that progresses on a BTK inhibitor.